New drug candidates and therapeutic targets for tuberculosis therapy

Ying Zhang, Katrin Post-Martens, Steven Denkin

Research output: Contribution to journalArticle

Abstract

Despite advances in chemotherapy and the BCG (Bacillus Calmette- Guérin) vaccine, tuberculosis remains a significant infectious disease. Although it can be cured, the therapy takes at least 6-9 months, and the laborious and lengthy treatment brings with it dangers of noncompliance, significant toxicity and drug resistance. The increasing emergence of drug resistance and the problem of mycobacterial persistence highlight the need to develop novel TB drugs that are active against drug resistant bacteria but, more importantly, kill persistent bacteria and shorten the length of treatment. Recent new and exciting developments in tuberculosis drug discovery show good promise of a possible revolution in the chemotherapy of tuberculosis.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalDrug Discovery Today
Volume11
Issue number1-2
DOIs
StatePublished - Jan 2006

Fingerprint

Tuberculosis
Drug Resistance
Pharmaceutical Preparations
Bacteria
BCG Vaccine
Drug Therapy
Drug Discovery
Bacillus
Communicable Diseases
Therapeutics

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

New drug candidates and therapeutic targets for tuberculosis therapy. / Zhang, Ying; Post-Martens, Katrin; Denkin, Steven.

In: Drug Discovery Today, Vol. 11, No. 1-2, 01.2006, p. 21-27.

Research output: Contribution to journalArticle

Zhang, Ying ; Post-Martens, Katrin ; Denkin, Steven. / New drug candidates and therapeutic targets for tuberculosis therapy. In: Drug Discovery Today. 2006 ; Vol. 11, No. 1-2. pp. 21-27.
@article{365b4bbd51234adc87b789491f665ca9,
title = "New drug candidates and therapeutic targets for tuberculosis therapy",
abstract = "Despite advances in chemotherapy and the BCG (Bacillus Calmette- Gu{\'e}rin) vaccine, tuberculosis remains a significant infectious disease. Although it can be cured, the therapy takes at least 6-9 months, and the laborious and lengthy treatment brings with it dangers of noncompliance, significant toxicity and drug resistance. The increasing emergence of drug resistance and the problem of mycobacterial persistence highlight the need to develop novel TB drugs that are active against drug resistant bacteria but, more importantly, kill persistent bacteria and shorten the length of treatment. Recent new and exciting developments in tuberculosis drug discovery show good promise of a possible revolution in the chemotherapy of tuberculosis.",
author = "Ying Zhang and Katrin Post-Martens and Steven Denkin",
year = "2006",
month = "1",
doi = "10.1016/S1359-6446(05)03626-3",
language = "English (US)",
volume = "11",
pages = "21--27",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "1-2",

}

TY - JOUR

T1 - New drug candidates and therapeutic targets for tuberculosis therapy

AU - Zhang, Ying

AU - Post-Martens, Katrin

AU - Denkin, Steven

PY - 2006/1

Y1 - 2006/1

N2 - Despite advances in chemotherapy and the BCG (Bacillus Calmette- Guérin) vaccine, tuberculosis remains a significant infectious disease. Although it can be cured, the therapy takes at least 6-9 months, and the laborious and lengthy treatment brings with it dangers of noncompliance, significant toxicity and drug resistance. The increasing emergence of drug resistance and the problem of mycobacterial persistence highlight the need to develop novel TB drugs that are active against drug resistant bacteria but, more importantly, kill persistent bacteria and shorten the length of treatment. Recent new and exciting developments in tuberculosis drug discovery show good promise of a possible revolution in the chemotherapy of tuberculosis.

AB - Despite advances in chemotherapy and the BCG (Bacillus Calmette- Guérin) vaccine, tuberculosis remains a significant infectious disease. Although it can be cured, the therapy takes at least 6-9 months, and the laborious and lengthy treatment brings with it dangers of noncompliance, significant toxicity and drug resistance. The increasing emergence of drug resistance and the problem of mycobacterial persistence highlight the need to develop novel TB drugs that are active against drug resistant bacteria but, more importantly, kill persistent bacteria and shorten the length of treatment. Recent new and exciting developments in tuberculosis drug discovery show good promise of a possible revolution in the chemotherapy of tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=32444448306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32444448306&partnerID=8YFLogxK

U2 - 10.1016/S1359-6446(05)03626-3

DO - 10.1016/S1359-6446(05)03626-3

M3 - Article

VL - 11

SP - 21

EP - 27

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 1-2

ER -